Human plasma glutathione peroxidase and symptom severity in schizophrenia

Biological Psychiatry

Volumn 45, Issue 11, 1999, Pages 1512-1515

  Yao, Jeffrey K ^a,b   Reddy, Ravinder D ^b   Van Kammen, Daniel P ^a,b  

^a VA Pittsburgh Healthcare System   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Haloperidol; Human plasma glutathione peroxidase; Oxidative stress; Psychosis; Schizophrenia

Indexed keywords

ANTIOXIDANT; GLUTATHIONE PEROXIDASE; HALOPERIDOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE LEVEL; HIGH RISK PATIENT; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE PEROXIDASE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 0032860431     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00184-X     Document Type: Article

References (24)

1. Abdalla D.S.P., Manteiro H.P., Olivera J.A.C., Bechara C.H. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem. 32:1986;805-807.
2. Andreasen N.C. Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry. 39:1982;784-794.
3. Bunney W.E., Hamburg D.A. Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry. 19:1963;280-294.
4. Eddington N.D., Young D. Sensitive electrochemical high-performance liquid chromatography assay for the simultaneous determination of haloperidol and reduced haloperidol. J Pharmacol Sci. 77:1988;541-543.
5. Flohé L., Aumann K.-D., Brigelius-Flohé R. A structure comparison of the glutathione peroxidase. Yagi K. Active Oxygens, Lipid Peroxides, and Antioxidants. 1993;299-311 CRC Press, New York.
6. Guy W. Abnormal involuntary movement scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. vol 338:1976;534-537 NIMH, Rockville, MD.
7. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry. 30:1991;795-805.
8. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illness. Psychopharmacol Bull. 31:1995;159-165.
9. Maddipati K.R., Gasparski C., Marnett L.J. Characterization of the hydro-peroxide-reducing activity of human plasma. Arch Biochem Biophys. 254:1987;9-17.
10. 31P nuclear magnetic resonance spectroscopy: Neurodevelopment and schizophrenia. Schizophr Bull. 19:1993;35-53.
11. Reddy R., Yao J.K. Free radical pathology in schizophrenia: A review. Prostaglandins Leukot Essent Fatty Acids. 55:1996;33-43.
12. Reddy R., Mahadik S.P., Mukherjee M., Murthy J.N. Enzymes of the antioxidant system in chronic schizophrenic patients. Biol Psychiatry. 30:1991;409-412.
13. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview for DSM-III-R - Patient Version. 1989;New York State Psychiatric Institute, New York.
14. Stoklasova A., Zapletalek M., Kudronova K., Randova Z. Glutathione peroxidase activity of blood in chronic schizophrenics. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 29:(suppl):1985;103-108.
15. Takahashi K., Avissar N., Whitin J., Cohen H. Purification and characterization of human plasma glutathione peroxidase: A selenoglycoprotein distinct from the known cellular enzyme. Arch Biochem Biophys. 256:1987;677-686.
16. Ursini F., Maiorino M., Gregolin C. The selenoenzyme phospholipid hydroperoxide glutathione peroxidase. Biochim Biophys Acta. 839:1985;62-70.
17. Yao J.K., van Kammen D.P. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophr Res. 11:1994;209-216.
18. 3H]arachidonic acid into platelet phospholipids of patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 55:1996;21-26.
19. Yao J.K., van Kammen D.P., Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr Res. 13:1994;227-232.
20. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res. 13:1994;217-226.
21. Yao J.K., van Kammen D.P., Gurklis J. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Psychiatry Res. 60:1996;11-21.
22. Yao JK, Reddy R, van Kammen DP (in press a): Reduced level of the antioxidant uric acid in schizophrenia. Psychiatry Res.
23. Yao JK, van Kammen DP, Reddy, RD (in press b): Neuroleptic effects on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res.
24. Yao JK, Reddy R, McElhinny LG, van Kammen DP (in press): Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res.